Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
7.92
-0.21 (-2.58%)
Dec 26, 2025, 4:00 PM EST - Market closed
Journey Medical Revenue
Journey Medical had revenue of $17.63M in the quarter ending September 30, 2025, with 20.52% growth. This brings the company's revenue in the last twelve months to $57.79M, up 0.04% year-over-year. In the year 2024, Journey Medical had annual revenue of $56.13M, down -29.11%.
Revenue (ttm)
$57.79M
Revenue Growth
+0.04%
P/S Ratio
3.07
Revenue / Employee
$1,448,756
Employees
41
Market Cap
214.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.13M | -23.05M | -29.11% |
| Dec 31, 2023 | 79.18M | 5.51M | 7.48% |
| Dec 31, 2022 | 73.67M | 10.54M | 16.69% |
| Dec 31, 2021 | 63.13M | 18.60M | 41.78% |
| Dec 31, 2020 | 44.53M | 9.61M | 27.52% |
| Dec 31, 2019 | 34.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DERM News
- 18 days ago - Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology - GlobeNewsWire
- 6 weeks ago - Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 7 weeks ago - Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 - GlobeNewsWire
- 2 months ago - Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference - GlobeNewsWire
- 2 months ago - Journey Medical Corporation to Participate in October 2025 Investor Conferences - GlobeNewsWire
- 4 months ago - Journey Medical: EMROSI's Ramp Puts Profitability On The Horizon - Seeking Alpha
- 4 months ago - Journey Medical Corporation to Participate in September 2025 Investor Conferences - GlobeNewsWire